Chiltern has opened a new process and technology center in Bangalore, India to further support its analytics, risk-based optimization, biometrics, and pharmacovigilance capabilities.
InDex Pharmaceuticals Holding AB has upgraded a deal with Parexel for its Phase IIb trial in Europe for ulcerative colitis, cancelling plans for US centres due to expense.
Mezzion has hired Pol Pharma and Halo Pharma and accused former CMO Dr Reddy’s of hiding manufacturing problems that cost its erectile dysfunction candidate, udenafil, US approval.
